XENE Stock — Price, Charts & Analysis

Xenon Pharmaceuticals Inc. (XENE) has no trailing P/E shown and a forward P/E of -12.29x. This places XENE in not enough valuation data territory based on the valuation data currently available on Worldtickers.

XENE trades with -12.29x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether XENE looks overvalued or undervalued.

XENE's P/E of -12.29x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

XENE's trailing EPS is -$4.74 and forward EPS is -$4.87.

EPS, or earnings per share, shows how much profit Xenon Pharmaceuticals Inc. generated for each share. XENE's trailing EPS is -$4.74, and investors usually prefer EPS that is positive and growing over time.

Xenon Pharmaceuticals Inc. has a market cap of $5.79B, making XENE a mid-cap stock based on the current market value shown on Worldtickers.

XENE's latest stock price on Worldtickers is $59.80. The latest move is -$2.52 or -4.04%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

XENE's quote includes a latest price of $59.80. The market open is $61.41. Previous close is $62.32. The intraday range is $59.64 to $62.51.

XENE is down in the latest quote, with a move of -$2.52 or -4.04%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

XENE generated $0.00 in trailing revenue.

No, XENE does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$409.20M.

Gross margin is 0.00%. Margins show how efficiently Xenon Pharmaceuticals Inc. turns revenue into profit.

Xenon Pharmaceuticals Inc. carries $6.42M and holds $930.69M in cash.

XENE holds $930.69M on its balance sheet.

XENE's book value per share is $12.84.

Institutions hold 108.16% of XENE shares. Insiders hold 0.11% of shares. Ownership mix helps investors understand how much of Xenon Pharmaceuticals Inc. is held by professional investors and company insiders.

XENE has 96.84M shares outstanding. Float shares are 90.95M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for XENE, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for XENE is -$4.87. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

XENE's trailing EPS is -$4.74. Forward EPS is -$4.87. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

XENE is in the Healthcare sector. Its earnings multiple is -12.29x. Compare these figures with sector peers before deciding whether Xenon Pharmaceuticals Inc. is stronger or weaker than average.

XENE trades at $59.80. The stock trades at -12.29x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Xenon Pharmaceuticals Inc.'s fundamentals.

XENE risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.63, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

XENE should be compared with companies in Biotechnology. Its earnings multiple is -12.29x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Xenon Pharmaceuticals Inc. (XENE) operates in Healthcare, specifically Biotechnology. Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorde

XENE trades on NasdaqGM. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

XENE stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Xenon Pharmaceuticals Inc.'s official website listed on Worldtickers is www.xenon-pharma.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Xenon Pharmaceuticals Inc. employs about 358 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Xenon Pharmaceuticals Inc. is headquartered in Burnaby, BC, Canada. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

XENE is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

XENE has traded between $35.60 and $72.66 over the past 52 weeks. At $59.80, it is 17.70% below the high and 67.98% above the low. The 52-week range helps gauge long-term price momentum.

XENE is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is $61.94 and its 200-day moving average is $51.62.

XENE's RSI is 38.49. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

XENE's latest RSI reading is 38.49, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for XENE is near $61.16. Key resistance is near $66.71. Breaks above resistance or below support can change the short-term technical setup.

XENE's nearest reported support level is $61.16. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

XENE's nearest reported resistance level is $66.71. A breakout above resistance can improve momentum, especially when volume confirms the move.

XENE trades about 1.33M shares daily on average. The latest displayed volume is 321.5K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

XENE's MACD is -0.54, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

XENE is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 38.49 (neutral). MACD is bearish. Nearest support is around $61.16. Resistance is around $66.71. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $63.58 (-5.94% from price). MA50 is $61.94 (-3.45% from price). MA200 is $51.62 (15.84% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. XENE's MA20 is $63.58. MA50 is $61.94. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

XENE's pivot is near $63.14. Support is near $61.16. Resistance is near $66.71. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for XENE is near $56.73. The next upper resistance zone is near $62.63. These levels help define risk and possible follow-through zones after a breakout or breakdown.

XENE's Bollinger range is roughly $60.83 to $66.33. Band width is near 8.65%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

XENE's ATR-based typical daily range is about 3.77%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 321.5K shares. Average volume is about 1.33M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

XENE's all-time high shown on Worldtickers is $72.66. Its all-time low is $2.10. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

XENE has a beta of 0.63, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.